Literature DB >> 6897039

Comparative study of the haemodynamic effects of oral molsidomine and isosorbide dinitrate in man.

A Vogt, H Kreuzer.   

Abstract

The haemodynamic effects of oral molsidomine 4 mg and sustained-release isosorbide dinitrate (ISDN) 40 mg have been compared in 10 patients recovering from acute myocardial infarction. After both drugs pulmonary arterial, pulmonary capillary wedge and systemic arterial blood pressure were reduced to about the same extent. The maximum effect was reached 1.5 to 2 h after ingestion of both drugs, but the effect of molsidomine declined during the following 2 h and control values were almost reached after 4 h. After ISDN there was no rebound during the observation period of 6 h. Unlike molsidomine, ISDN reduced total peripheral resistance, so cardiac output and stroke volume index remained constant despite the reduction in cardiac preload. It is concluded that sustained release ISDN 40 mg and molsidomine 4 mg are about equieffective doses in terms of reduction of cardiac preload, but that the effect of molsidomine is of shorter duration. Since molsidomine alone causes venous pooling, cardiac output and stroke volume index are reduced, which may be an untoward side effect in patients with severe heart failure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6897039     DOI: 10.1007/bf01061370

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  [Effect of sublingual isosorbide dinitrate on hemodynamics in coronary patients with and without congestive heart failure (author's transl)].

Authors:  R Wolf; O A Beck; F Habel; H Hochrein
Journal:  Z Kardiol       Date:  1977-08

2.  Hypotensive action of N-ethoxycarbonyl3-morpholinosydnonimine, SIN-10.

Authors:  K Kikuchi; M Hirata; A Nagaoka
Journal:  Jpn J Pharmacol       Date:  1970-03

3.  [Effect of Molsidomin on the hemodynamics and working tolerance of patients with angina pectoris].

Authors:  J Slany; H Mösslacher; R Schmoliner; G Krinik
Journal:  Med Welt       Date:  1976-12-03

4.  [Effects of molsidomin on left ventricular function and volume in patients with coronary heart disease (author's transl)].

Authors:  K R Karsch; H Blanke; H Kreuzer; K P Rentrop
Journal:  Z Kardiol       Date:  1979-02

5.  The long-acting hemodynamic effects of isosorbide dinitrate.

Authors:  T Sweatman; G Strauss; A Selzer; K E Cohn
Journal:  Am J Cardiol       Date:  1972-04       Impact factor: 2.778

6.  The mode of hypotensive action of newly synthesized sydnonimine derivatives.

Authors:  K Hashimoto; N Taira; M Hirata
Journal:  Arzneimittelforschung       Date:  1971-09

7.  Effects of N-ethoxycarbonyl-3-morpholinosyndnonimine (SIN-10) on the cardiovascular system.

Authors:  F Takenaka; N Takeya; T Ishihara; S Inoue; E Tsutsumi
Journal:  Jpn J Pharmacol       Date:  1970-06

8.  Haemodynamic effects of molsidomin.

Authors:  K R Karsch; K P Rentrop; H Blanke; H Kreuzer
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

9.  Comparative study of nitroglycerin and molsidomine. Effects on the integrated systemic venous bed and the arterial pressure in dogs.

Authors:  E Grund; E R Müller-Ruchholtz; E R Lapp; H M Lösch; W Lochner
Journal:  Arzneimittelforschung       Date:  1978

10.  Molsidomine in the treatment of patients with angina pectoris.

Authors:  P A Majid; P J DeFeyter; E E Van der Wall; R Wardeh; J P Roos
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

  10 in total
  2 in total

1.  Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.

Authors:  R Bergstrand; A Vedin; C Wilhelmsson; L E Peterson; J Chamberlain; D Dell; L A Stevens; J Ostrowski
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Clinical pharmacokinetics of molsidomine.

Authors:  B Rosenkranz; B R Winkelmann; M J Parnham
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.